Effect of Citalopram on Brain Serotonin Release in Experimental Hepatic EncephalopathyImplications for Thymoleptic Drug Safety in Liver Insufficiency
作者:
Peter Bergqvist,
Cecilia Wikell,
Stephan Hjorth,
Gustav Apelqvist,
Finn Bengtsson,
期刊:
Clinical Neuropharmacology
(OVID Available online 1997)
卷期:
Volume 20,
issue 6
页码: 511-522
ISSN:0362-5664
年代: 1997
出版商: OVID
关键词: Drug safety;Hepatic encephalopathy;Reuptake;Serotonin.
数据来源: OVID
摘要:
In the present study, effects of citalopram (CIT) on brain 5-hydroxytryptamine (5-HT) release in experimental chronic hepatic encephalopathy (HE) were investigated. Neocortical administration of CIT (1.0 μM) increased the brain 5-HT output to a similar extent in portacaval shunted (PCS) rats and sham-operated controls, indicating that a previous described mismatch between increased 5-HT turnover and unchanged release in PCS rats is not explained by an accelerated brain 5-HT reuptake. Subsequent systemic administration of CIT (5 mg/kg subcutaneously) resulted in a more pronounced attenuation of the brain 5-HT release in PCS rats than in sham-operated controls, possibly indicating a higher susceptibility to indirect mid-brain 5-HT1Aautoreceptor activation in experimental portal-systemic encephalopathy (PSE). A KCl (60 mM) challenge in the presence of locally administered CIT (1 μM) induced a more marked neocortical 5-HT response in PCS rats than in sham-operated controls, confirming previous results of a higher than normal amount of 5-HT available for depolarization-induced release in PCS rats. Although the pharmacodynamic parameters in this study was investigated for CIT, the likelihood of a parallel pharmacokinetic alteration existing for this drug in the PCS condition also was indicated. It is thus suggested that otherwise generally safe central nervous system 5-HT-active drugs may represent a potential hazard in patients with liver failure with or without PSE.
点击下载:
PDF
(749KB)
返 回